Latest RareDiseases News and Updates : RareDiseases updates, RareDiseases News , RareDiseases around the world

Nishadil

Washington | 24°C (overcast clouds)

A Bold New Chapter: Rare Ventures Launches with a $25 Million Bet on a Smarter Approach to Rare Disease Therapies

Top story

A Bold New Chapter: Rare Ventures Launches with a $25 Million Bet on a Smarter Approach to Rare Disease Therapies

In focus

Latest feed

Rare Disease Makers Push Back on Medicare Price‑Cut Pilots

Rare‑Disease Makers Push for Medicare Price‑Cut Exemptions

Vertex Pharmaceuticals Makes a Major Play, Acquiring Crinetics in a Near-$5 Billion Deal

Biotech Power Play: Vertex's Bold Leap into Endocrine Therapies

Latest headlines

A $10 Billion Shake-Up: Vertex Pharmaceuticals to Acquire Crinetics in Major Cash Deal

A $10 Billion Shake-Up: Vertex Pharmaceuticals to Acquire Crinetics in Major Cash Deal

Child with Rare Disease Denied NRPD Aid – Centre Takes Matter to High Court

Child with Rare Disease Denied NRPD Aid – Centre Takes Matter to High Court

A Paradigm Shift: CAR T-Cell Therapy Offers New Hope for Stiff Person Syndrome

A Paradigm Shift: CAR T-Cell Therapy Offers New Hope for Stiff Person Syndrome

The Unraveling of Kezar Life Sciences: How an FDA Delay Triggered a Biotech Startup's Collapse

The Unraveling of Kezar Life Sciences: How an FDA Delay Triggered a Biotech Startup's Collapse

A Ray of Hope for Rare Skin Conditions: Disc Medicine Completes Bitopertin Trial Enrollment

A Ray of Hope for Rare Skin Conditions: Disc Medicine Completes Bitopertin Trial Enrollment

Quoin Pharmaceuticals Unveils Significant Clinical Progress and Strong Financial Standing for 2025

Quoin Pharmaceuticals Unveils Significant Clinical Progress and Strong Financial Standing for 2025

Aurora Investments Makes Bold Bet on Groundbreaking Healthcare Stock, Sets Ambitious $260 Price Target

Aurora Investments Makes Bold Bet on Groundbreaking Healthcare Stock, Sets Ambitious $260 Price Target

A Major Setback: FDA Halts uniQure's Huntington's Gene Therapy Trial

A Major Setback: FDA Halts uniQure's Huntington's Gene Therapy Trial

The FDA's Bold New Vision: Could One Clinical Trial Be Enough for Drug Approval?

The FDA's Bold New Vision: Could One Clinical Trial Be Enough for Drug Approval?

A Glimmer of Hope: CRISPR's Promise for Children with Pura Syndrome

A Glimmer of Hope: CRISPR's Promise for Children with Pura Syndrome

A Bold Bet on the Future: Regeneron's $150M Investment in Gene Writing

A Bold Bet on the Future: Regeneron's $150M Investment in Gene Writing

A New Chapter in Rare Disease Treatment: Omeros and Novo Nordisk Finalize Landmark Zaltenibart Deal

A New Chapter in Rare Disease Treatment: Omeros and Novo Nordisk Finalize Landmark Zaltenibart Deal

The Quiet Hum of Hope and High Stakes: Unpacking the Future of Huntington's Treatment

The Quiet Hum of Hope and High Stakes: Unpacking the Future of Huntington's Treatment

The Unseen Struggle: Navigating the Complexities of Systemic Mastocytosis and the Crucial Call for Early Referral

The Unseen Struggle: Navigating the Complexities of Systemic Mastocytosis and the Crucial Call for Early Referral

The FDA's Tightening Grip: A Crucible for Biotech's Biggest Bets

The FDA's Tightening Grip: A Crucible for Biotech's Biggest Bets

The Great Drug Price Tug-of-War: Democrats Target a Rare Loophole

The Great Drug Price Tug-of-War: Democrats Target a Rare Loophole

The High Stakes Game: Sarepta, Duchenne, and the Edge of Hope

The High Stakes Game: Sarepta, Duchenne, and the Edge of Hope

A Brave New World of Medicine: Unpacking the Promise and Peril of Biotech Drugs

A Brave New World of Medicine: Unpacking the Promise and Peril of Biotech Drugs

PTC Therapeutics Welcomes Fresh Talent with Strategic Equity Grants: A Glimpse into Future Growth

PTC Therapeutics Welcomes Fresh Talent with Strategic Equity Grants: A Glimpse into Future Growth

A Beacon of Progress: CSL's Swiss Marvel Redefines the Future of Healing

A Beacon of Progress: CSL's Swiss Marvel Redefines the Future of Healing

A Pharmaceutical Titan's Bold Bet: Novartis Swallows Avidity in a $12 Billion Quest for Genetic Breakthroughs

A Pharmaceutical Titan's Bold Bet: Novartis Swallows Avidity in a $12 Billion Quest for Genetic Breakthroughs

The Whisper Becomes a Roar: Why Novartis Needs Avidity’s RNA Revolution, Now More Than Ever

The Whisper Becomes a Roar: Why Novartis Needs Avidity’s RNA Revolution, Now More Than Ever

The Biotech Gambit: Novartis Reportedly Eyes Avidity in a High-Stakes Acquisition

The Biotech Gambit: Novartis Reportedly Eyes Avidity in a High-Stakes Acquisition

The Big Pharma Buzz: Why Novartis Might Be Eyeing Avidity's RNA Magic

The Big Pharma Buzz: Why Novartis Might Be Eyeing Avidity's RNA Magic

FDA Unleashes Game-Changing Incentive: Priority Review Vouchers Set to Revolutionize Drug Development

FDA Unleashes Game-Changing Incentive: Priority Review Vouchers Set to Revolutionize Drug Development

Baby KJ's Milestone: Unlocking Personalized CRISPR Gene Editing for the Masses

Baby KJ's Milestone: Unlocking Personalized CRISPR Gene Editing for the Masses

$Monopar's Breakthrough in Wilson Disease: A New Dawn with AstraZeneca's Shadow$

Monopar's Breakthrough in Wilson Disease: A New Dawn with AstraZeneca's Shadow

Biohaven's Breakthrough Bid: Navigating FDA Flexibility for Spinocerebellar Ataxia's Future

Biohaven's Breakthrough Bid: Navigating FDA Flexibility for Spinocerebellar Ataxia's Future

Baby KJ's Miraculous CRISPR Journey: A New Dawn for Personalized Gene Editing

Baby KJ's Miraculous CRISPR Journey: A New Dawn for Personalized Gene Editing

The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs

The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs

A Mother's Unwavering Intuition: The Rare Diagnosis of Cockayne Syndrome

A Mother's Unwavering Intuition: The Rare Diagnosis of Cockayne Syndrome

PGI Chandigarh Unlocks Future of Paediatric Care with Next-Gen Genetic Sequencing Facility

PGI Chandigarh Unlocks Future of Paediatric Care with Next-Gen Genetic Sequencing Facility

Biotech Giant Rallybio Exits CT: Dozens Face Layoffs as Facility Closes

Biotech Giant Rallybio Exits CT: Dozens Face Layoffs as Facility Closes

The Boy Who Stopped Time: Oliver's Battle Against a Rare Tumor That Halted His Growth at 12

The Boy Who Stopped Time: Oliver's Battle Against a Rare Tumor That Halted His Growth at 12

The Unprecedented Life of the World's Oldest Progeria Survivor

The Unprecedented Life of the World's Oldest Progeria Survivor

Harmony Bio Faces Significant Setback: Fragile X Syndrome Therapy Misses Primary Endpoint in Pivotal Trial

Harmony Bio Faces Significant Setback: Fragile X Syndrome Therapy Misses Primary Endpoint in Pivotal Trial

Pioneering Partnership: GCCL and Frontage Laboratories Unite to Revolutionize Global Clinical Trials

Pioneering Partnership: GCCL and Frontage Laboratories Unite to Revolutionize Global Clinical Trials

European Experts Back Two AstraZeneca Breakthroughs: New Hope for Rare Diseases

European Experts Back Two AstraZeneca Breakthroughs: New Hope for Rare Diseases

Load more